The Academy of Managed Care Pharmacy (AMCP) is the leading professional organization for practitioners invested in the development and implementation of value-based care pathways within the managed care setting. Since its founding in 1988, AMCP boasts a membership of greater than 8000, comprised of pharmacists, physicians, nurses, mid-level providers, and other medical practitioners. The organization’s 2017 Annual Meeting featured more than 300 abstract and poster presentations of research pertaining to treatment efficacy, cost-effectiveness, and other relevant topics within the managed care continuum.
The abstracts presented at the AMCP Annual Meeting represented all areas of health care, with particular focus on health care and emerging care models within oncology, endocrinology and metabolic diseases, behavioral and mental health disorders, and diseases of the nervous system. Studies offered cost-effectiveness data on several recently approved therapies, including pazopanib (Votrient, Novartis), daratumumab (Darzalex, Janssen), and pomalidomide (Pomalyst, Celgene).
Implementing Clinical Pathways for Multiple Myeloma
Multiple myeloma represents a key area for clinical pathway development.
Pazopanib More Cost-Effective Than Sunitinib for Patients With Renal Cell Carcinoma
Medicare patients with advanced renal cell carcinoma benefit from lower costs and hospital admissions if treated with pazopanib (Votrient, Novartis) rather than sunitinib (Sutent, Pfizer).
Cost-Effectiveness Analysis Reveals Optimal Immunotherapy for Metastatic NSCLC
Recent research suggests a particular immunotherapy may be less costly and offer time savings compared with nivolumab for patients with metastatic non-small cell lung cancer.
